Join Fund Library now and get free access to personalized features to help you manage your investments.
Sector Equity
Click for more information on Fundata’s ESG Grade
Click for more information on Fundata’s ESG Grade.
2012
Click for more information on Fundata’s FundGrade
|
NAVPS (05-07-2024) |
$78.96 |
|---|---|
| Change |
$0.96
(1.23%)
|
As at March 31, 2024
As at March 31, 2024
As at February 29, 2024
Loading...
Inception Return (November 01, 2000): 9.30%
| Row Heading | Return | Annualized Return | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Mth | 3 Mth | 6 Mth | YTD | 1 Yr | 2 Yr | 3 Yr | 4 Yr | 5 Yr | 6 Yr | 7 Yr | 8 Yr | 9 Yr | 10 Yr | |
| Fund | 1.40% | 10.17% | 15.71% | 10.17% | 13.51% | 6.97% | 5.31% | 11.44% | 9.32% | 10.85% | 11.03% | 11.59% | 8.80% | 13.17% |
| Benchmark | 4.14% | 6.62% | 15.26% | 6.62% | 13.96% | 3.95% | 9.11% | 16.99% | 9.96% | 9.65% | 8.48% | 9.70% | 7.76% | 7.67% |
| Category Average | 1.75% | 21.53% | 21.53% | 10.46% | 26.42% | 7.93% | 5.18% | 15.21% | 11.07% | 11.30% | 11.63% | 12.17% | 10.44% | 11.78% |
| Category Rank | 129 / 194 | 76 / 193 | 97 / 189 | 76 / 193 | 106 / 173 | 80 / 155 | 69 / 140 | 70 / 134 | 68 / 123 | 43 / 115 | 35 / 90 | 36 / 90 | 41 / 83 | 30 / 72 |
| Quartile Ranking | 3 | 2 | 3 | 2 | 3 | 3 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 2 |
| Return % | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund | 3.80% | -2.74% | 0.39% | -0.60% | 0.85% | -3.45% | -1.99% | 3.23% | 3.81% | 3.47% | 5.01% | 1.40% |
| Benchmark | 2.90% | -4.95% | 3.36% | 2.58% | -1.37% | -3.33% | -3.21% | 7.48% | 3.91% | 0.55% | 1.82% | 4.14% |
14.28% (January 2015)
-14.45% (March 2001)
| Return % | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Fund | 42.76% | 34.71% | -13.91% | 19.00% | 9.16% | 22.16% | 25.93% | 11.06% | -6.71% | 0.35% |
| Benchmark | 10.55% | -8.32% | 21.08% | 9.10% | -8.89% | 22.88% | 5.60% | 25.09% | -5.84% | 11.75% |
| Category Average | 17.30% | 16.21% | -0.43% | 20.39% | 1.55% | 22.37% | 29.99% | 15.34% | -25.24% | 26.53% |
| Quartile Ranking | 1 | 1 | 4 | 2 | 1 | 2 | 3 | 3 | 2 | 4 |
| Category Rank | 2/ 72 | 4/ 83 | 75/ 90 | 41/ 90 | 16/ 110 | 56/ 121 | 67/ 131 | 89/ 136 | 41/ 153 | 124/ 164 |
42.76% (2014)
-13.91% (2016)
| Name | Percent |
|---|---|
| US Equity | 88.71 |
| International Equity | 10.66 |
| Foreign Corporate Bonds | 0.56 |
| Cash and Equivalents | 0.07 |
| Name | Percent |
|---|---|
| Healthcare | 92.65 |
| Consumer Services | 1.02 |
| Fixed Income | 0.56 |
| Financial Services | 0.21 |
| Cash and Cash Equivalent | 0.07 |
| Other | 5.49 |
| Name | Percent |
|---|---|
| North America | 89.34 |
| Europe | 9.14 |
| Asia | 1.20 |
| Latin America | 0.04 |
| Africa and Middle East | 0.02 |
| Other | 0.26 |
| Name | Percent |
|---|---|
| Eli Lilly and Co | 9.99 |
| UnitedHealth Group Inc | 6.14 |
| Intuitive Surgical Inc | 4.17 |
| Merck & Co Inc | 4.06 |
| Thermo Fisher Scientific Inc | 4.05 |
| Stryker Corp | 3.66 |
| Elevance Health Inc | 3.56 |
| Danaher Corp | 2.95 |
| Regeneron Pharmaceuticals Inc | 2.70 |
| Vertex Pharmaceuticals Inc | 2.12 |
TD Health Sciences Fund - F-Series
Median
Other - Sector Equity
| Standard Deviation | 13.50% | 14.30% | 16.04% |
|---|---|---|---|
| Beta | 0.50% | 0.44% | 0.46% |
| Alpha | 0.01% | 0.05% | 0.10% |
| Rsquared | 0.24% | 0.23% | 0.13% |
| Sharpe | 0.26% | 0.56% | 0.77% |
| Sortino | 0.32% | 0.81% | 1.09% |
| Treynor | 0.07% | 0.18% | 0.27% |
| Tax Efficiency | 100.00% | 100.00% | 100.00% |
| Volatility |
|
|
|
| Key Ratio | 1 Yr | 3 Yr | 5 Yr | 10 Yr |
|---|---|---|---|---|
| Standard Deviation | 9.83% | 13.50% | 14.30% | 16.04% |
| Beta | 0.54% | 0.50% | 0.44% | 0.46% |
| Alpha | 0.06% | 0.01% | 0.05% | 0.10% |
| Rsquared | 0.50% | 0.24% | 0.23% | 0.13% |
| Sharpe | 0.86% | 0.26% | 0.56% | 0.77% |
| Sortino | 1.91% | 0.32% | 0.81% | 1.09% |
| Treynor | 0.15% | 0.07% | 0.18% | 0.27% |
| Tax Efficiency | 100.00% | 100.00% | 100.00% | 100.00% |
The E, S, and G scores are averaged for each security in the portfolio, to arrive at an ESG score for each security. We take the portfolio weighted average of the ESG scores for each fund and rank them against their peers to arrive at the Fundata ESG Score from 0-100.
Three scores under the Environment bucket are averaged to yield the Fundata Environment Score for each fund from 0-100: (1) Pollution Prevention, (2) Environmental Transparency, (3) Resource Efficiency.
Six scores under the Social bucket are averaged to yield the Fundata Social Score for each fund from 0-100. (1) Compensation and Satisfaction, (2) Diversity and Rights, (3) Education and Work Conditions, (4) Community and Charity, (5) Human Rights, (6) Sustainability Integration.
Three scores under the governance bucket are averaged to yield the Fundata Governance Score for each fund from 0-100: (1) Board Effectiveness, (2) Management Ethics, (3) Disclosure and Accountability.
Powered by OWL Analytics. For more information, please contact Fundata Canada.
| Start Date | November 01, 2000 |
|---|---|
| Instrument Type | Mutual Fund |
| Share Class | Fee Based Advice |
| Legal Status | Trust |
| Sales Status | Open |
| Currency | CAD |
| Distribution Frequency | Annual |
| Assets ($mil) | - |
| FundServ Code | Load Code | Sales Status |
|---|---|---|
| TDB420 |
The fundamental investment objective of the Fund is to achieve long-term capital appreciation by investing primarily in equity securities of companies located in the United States and other countries, that are engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences.
The sub-adviser seeks to achieve the fundamental investment objective of the Fund by investing at least 65% of the Fund’s total assets in common stocks of companies in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences. The sub-adviser divides the health sciences sector into four main areas: pharmaceuticals, health care services, products and devices, and biotechnology firms.
| Name | Start Date |
|---|---|
| Ziad Bakri | 07-23-2015 |
| TD Asset Management Inc. | 09-10-2020 |
| Fund Manager | TD Asset Management Inc. |
|---|---|
| Advisor | TD Asset Management Inc. |
| Custodian | CIBC Mellon Trust Company |
| Registrar | The Toronto-Dominion Bank |
| Distributor | TD Investment Services Inc |
| Auditor | Ernst & Young LLP |
| RSP Eligible | Yes |
|---|---|
| PAC Allowed | Yes |
| PAC Initial Investment | - |
| PAC Subsequent | - |
| SWP Allowed | Yes |
| SWP Min Balance | 1,000 |
| SWP Min Withdrawal | 100 |
| MER | 1.39% |
|---|---|
| Management Fee | 1.25% |
| Load | No Load |
| FE Max | - |
| DSC Max | - |
| Trailer Fee Max (FE) | - |
| Trailer Fee Max (DSC) | - |
| Trailer Fee Max (NL) | 0.00% |
| Trailer Fee Max (LL) | - |
Join Fund Library now and get free access to personalized features to help you manage your investments.
Fund Library
